Micronbrane Medical
Zhubei, Taiwan· Est.
A Taiwan startup delivering host‑depletion and contamination‑reduction solutions to accelerate mNGS‑based infectious‑disease diagnostics.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A Taiwan startup delivering host‑depletion and contamination‑reduction solutions to accelerate mNGS‑based infectious‑disease diagnostics.
Infectious DiseasesAntimicrobial ResistanceMicrobiome Research
Technology Platform
Proprietary zwitterionic membrane that selectively depletes host DNA and reduces environmental contamination, enabling higher‑sensitivity, lower‑cost metagenomic NGS.
Opportunities
Rapid growth of clinical metagenomics and increasing demand for rapid, cost‑effective infectious‑disease diagnostics provide a large addressable market for Micronbrane’s host‑depletion solutions.
Risk Factors
Regulatory clearance timelines, competition from integrated NGS platforms, and dependence on broader adoption of mNGS in clinical laboratories could limit scaling.
Competitive Landscape
Competitors include Illumina, QIAGEN, and Twist Bioscience, which focus on sequencing and library prep; Micronbrane differentiates through upstream host‑depletion chemistry that improves sensitivity and reduces cost.